Cancer in patients with rheumatic diseases exposed to different biologic and targeted synthetic DMARDs in real-world clinical practice: data from a multicenter register
14/08/2023
I. Castrejon1,2, J. Molina Collada1,2, C. Perez-Garcia3 , P. Vela-Casasempere4 , C. Diaz-Torne5 , C. Bohórquez6 , J. M. Blanco7 , F. Sánchez-Alonso8 on behalf of BIOBADASER.
EULAR 2022
DOI: 10.1136/annrheumdis-2022-eular.3834
https://ard.bmj.com/content/81/Suppl_1/1063